Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corp    EW

Delayed Quote. Delayed  - 09/30 10:03:26 pm
120.56 USD   +1.09%
09/30 EDWARDS LIFESCI : The Medical Device Industry's Focus on Cardio and ..
09/19 EDWARDS LIFESCI : Sapien 3 Transcatheter Heart Valve Receives Expand..
09/01 EDWARDS LIFESCI : To Present At The 11th Annual Wells Fargo Healthca..
News SummaryMost relevantAll newsSector news 

Edwards Lifesciences Corp : Edwards Lifesciences' Chairman and CEO to Exercise Stock Options Under 10b5-1 Stock Trading Plan

share with twitter share with LinkedIn share with facebook
share via e-mail
03/01/2013 | 04:37pm CEST

IRVINE, CA, March 01, 2013 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that its chairman and chief executive officer, Michael A. Mussallem, has adopted a pre-arranged stock trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934. In May 2013, the plan will begin exercising stock options, the vast majority of which are scheduled to expire in 2014.

The plan anticipates the exercise and sale of 29,500 shares per month at market prices between May 2013 and April 2014. Rule 10b5-1 allows corporate executives to adopt stock trading plans to buy or sell shares of company stock when they are not in possession of material, non-public information. Mussallem plans to enter into similar types of trading plans each year as stock options near their expiration dates in order to spread sales evenly over an extended period of time.

Under the company's stock ownership guidelines, Mussallem is required to own shares of company stock with an aggregate market value equal to six times his base salary. At the conclusion of the plans, Mussallem will still hold shares well in excess of the number required to meet these guidelines. Transactions under these plans will be disclosed publicly through Form 144 and Form 4 filings with the U.S. Securities and Exchange Commission. The Form 4 filings will also be posted on Edwards' investor relations Web site at ir.edwards.com.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at edwards.com.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

# # #

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
09/30 EDWARDS LIFESCIENCES : The Medical Device Industry's Focus on Cardio and Cardiov..
09/29 EDWARDS LIFESCIENCES : Federal Contracts Awarded by Federal Agencies in Iowa (Se..
09/29 EDWARDS LIFESCIENCES : An Application for the Trademark "PERIMOUNT" Has Been Fil..
09/28 EDWARDS LIFESCIENCES : Assigned Patent
09/19 EDWARDS LIFESCIENCES : Sapien 3 Transcatheter Heart Valve Receives Expanded Indi..
09/15 EDWARDS LIFESCIENCES' : Trademark Application for "TRUWAVE IQ" Filed
09/15 EDWARDS LIFESCIENCES : An Application for the Trademark "TIME IN TARGET" Has Bee..
09/15 EDWARDS LIFESCIENCES : Patent Issued for Apparatus and Method for Stent Shaping ..
09/15 EDWARDS LIFESCIENCES : Trademark Application for "MAGNA EASE" Filed by Edwards L..
09/14 EDWARDS LIFESCIENCES : Federal Contracts Awarded by Federal Agencies in Iowa (Se..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
09/27DJBOSTON SCIENTIFIC : to Buy EndoChoice
09/01DJPHILIPS : Appoints IBM Executive Sophie Bechu as Operations Head
08/17DJAGILENT TECHNOLOGIES : Tech Tapers Annual Outlook Amid Slowing Life Sciences Sal..
08/15DJFisher & Paykel Files Patent Infringement Claim Against ResMed
08/02DJCERNER : Edges Annual Revenue Guidance Lower
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
09/29 Edwards' INSPIRIS RESILIA valve receives CE mark
09/19 Expanded label for Edwards' SAPIEN 3 valve OK'd in Europe
09/13 Steps To Survive The Rate Hike - Cramer's Mad Money (9/12/16)
09/08 VALUATION DASHBOARD : Healthcare - Update
08/25 Dancing With TINA
Financials ($)
Sales 2016 2 997 M
EBIT 2016 819 M
Net income 2016 596 M
Finance 2016 800 M
Yield 2016 -
P/E ratio 2016 44,56
P/E ratio 2017 35,74
EV / Sales 2016 8,30x
EV / Sales 2017 7,33x
Capitalization 25 665 M
More Financials
Duration : Period :
Edwards Lifesciences Corp Technical Analysis Chart | EW | US28176E1082 | 4-Traders
Full-screen chart
Technical analysis trends EDWARDS LIFESCIEN...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 124 $
Spread / Average Target 3,2%
Consensus details
EPS Revisions
More Estimates Revisions
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Stanton J. Rowe Chief Scientific Officer & VP-Advanced Technology
John P. McGrath Vice President-Quality, Regulatory & Clinical
John T. Cardis Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PHILIPS11.97%28 124
ILLUMINA, INC.-5.36%26 631
More Results